ClinicalTrials.gg
RecruitingNCT04358146STELLARUpdated May 4, 2026

Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)

An interventional study of Experimental Infant formula and Infant formula thickened with locust bean gum in Gastroesophageal Reflux in Children, sponsored by United Pharmaceuticals. Recruiting at 12 sites in 4 countries. Open to participants aged 2 Weeks to 4 Months. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by United Pharmaceuticals · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
2 Weeks to 4 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Gastroesophageal Reflux with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Gastroesophageal Reflux · France.

Planned enrollment
14th of 47
346 · median 130
Started
2023
with 2 others
No phase
18 of 62
5 open now
Registered
51st of 62
by date
Lead sponsor
3 of 62
United Pharmaceuticals

Among the 62 studies in Gastroesophageal Reflux with a site in France, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 with no phase, and was the 51st registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

6 of the 62 studies in Gastroesophageal Reflux with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 2 Weeks to 4 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Gastroesophageal Reflux with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.

Read the detailed description

The study duration is 1 month and 2 days. It is possible to add 2 additional months (optional).

The 2 first days (from D-3 to D0) correspond to the pre-selection period. These 2 days are followed by the follow-up month (from D0 to D30). It is possible to add an optional follow up of 2 months (form D30 to D90).

03

Conditions studied

  • Gastroesophageal Reflux in Children

Keywords

  • Reflux
04

Who can participate

Ages eligible
2 Weeks to 4 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days,
  • exclusive or predominant formula feeding
  • whose parents signed

Exclusion criteria

Exclusion Criteria:

  • preterm infants or birthweight \<2500g
  • Post enteritis lactose intolerance
  • Suspected or diagnosed cow's milk protein allergy requiring an eviction diet
  • Use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). All these medications have to be stopped at least 7 days before inclusion visit (V1)
  • Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
346 participants (estimated)

Study arms

  • Experimental
    Test

    new thickened infant formula containing fibres

    Other: Experimental Infant formula

  • Active comparator
    Control

    infant formula thickened with locust bean

    Other: Infant formula thickened with locust bean gum

Interventions

  • OtherExperimental Infant formula

    Exclusive formula feeding with the new infant formula thickened with fibers

  • OtherInfant formula thickened with locust bean gum

    Exclusive formula feeding with the formula thickened with locust bean

06

What researchers measure

Primary outcomes

  1. Frequency of regurgitation

    Decrease of the daily number of regurgitation between baseline and day 14

    Time frame: Day 14

Secondary outcomes

  1. Frequency of regurgitations

    Change in the daily number of regurgitation between baseline and day 30 / day 90

    Time frame: Day 30, Day 90

  2. Severity of regurgitation episodes

    Severity of regurgitations will be assessed using the adapted Vandenplas' score (range: 0 to 6; higher scores indicate more severe regurgitation)

    Time frame: Day 14, Day 30, Day 90

  3. Stools' frequency

    Average daily stool's number

    Time frame: Day 14, Day 30, Day 90

  4. Stools' consistency

    The Amsterdam Infant Stool Scale (AISS) (consistency categories: A \[watery\] to D \[hard\]; higher categories indicate firmer stools)

    Time frame: Day 14, Day 30, Day 90

  5. Frequency of diarrhea

    Frequency : Occurence of diarrhea

    Time frame: Day 14, Day 30, Day 90

  6. Severity of diarrhea

    Severity of diarrhea assessed using a study-specific score calculated as the sum of the products of each watery stool and its volume over 2 days (minimum score: 6; no upper limit; higher scores indicate more severe diarrhea)

    Time frame: Day 14, Day 30, Day 90

  7. Frequency of constipation

    Occurence of constipation

    Time frame: Day 14, Day 30, Day 90

  8. Severity of constipation

    Severity of constipation assessed using a study-specific score (range: 1 to 3; higher scores indicate more severe constipation)

    Time frame: Day 14, Day 30, Day 90

  9. Crying time

    Crying time reported by parents in class (Min : Less than 10 min / Max : 3h or more)

    Time frame: Day 14, Day 30, Day 90

  10. Feeding refusal

    Percentage of parents reporting feeding refusal by frequency of occurence (Never / Rarely / Sometimes / Often / Always)

    Time frame: Day 14, Day 30, Day 90

  11. Abnormal posturing

    Percentage of parents reporting abnormal posturing by frequency of occurence (Never / Rarely / Sometimes / Often / Always)

    Time frame: Day 14, Day 30, Day 90

  12. Sleep quality

    Percentage of parents reporting poor sleep quality (Excellent / Good / Fair / Poor)

    Time frame: Day 14, Day 30, Day 90

  13. Anthropometric parameters - Weight

    Body weight measured in kilograms (kg)

    Time frame: Day 14, Day 30, Day 90

  14. Anthropometric parameters - Length

    Body length measured in centimeters (cm)

    Time frame: Day 14, Day 30, Day 90

  15. Anthropometric parameters - Head circumference

    Head circumference measured in centimeters (cm)

    Time frame: Day 14, Day 30, Day 90

  16. Anthropometric parameters - BMI

    Body mass index calculated as kg/m²

    Time frame: Day 14, Day 30, Day 90

  17. Anthropometric parameters - Weight-for-height z-score

    Weight-for-height z-score calculated according to WHO Child Growth Standards

    Time frame: Day 14, Day 30, Day 90

  18. Use of drug treatments

    Frequency of use of proton-pump inhibitors, prokinetics, other GERD treatment

    Time frame: Day 14, Day 30, Day 90

  19. Parents' satisfaction

    Parental satisfaction assessed using a 5-point Likert scale (Very satisfied, Fairly well satisfied, Somewhat dissatisfied, Very dissatisfied, No opinion)

    Time frame: Day 14, Day 30, Day 90

  20. Investigator's satisfaction

    Investigator satisfaction assessed using a 5-point Likert scale (Very satisfied, Fairly well satisfied, Somewhat dissatisfied, Very dissatisfied, No opinion)

    Time frame: Day 14, Day 30, Day 90

07

Study locations

10 of 12 sites recruiting
  • Center_14
    Namur, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • Center_15
    Thuin, Belgium
    Recruiting
    • MD · Contact
  • Center_09
    Castelnau-le-Lez, France
    Active, not recruiting

    Not enrolling at this site.

  • Center_02
    Étampes, France
    Recruiting
    • MD · Contact
  • Center_05
    Libourne, France
    Recruiting
    • MD · Contact
  • Centre_10
    Maromme, France
    Recruiting
    • MD · Contact
  • Center_16
    Nice, France
    Recruiting
    • MD · Contact
  • Center_08
    Vincennes, France
    Recruiting
    • MD · Contact
  • Center_01
    Athens, Greece
    Recruiting
    • MD · Contact
  • Center_11
    Thessaloniki, Greece
    Recruiting
    • Ioanni, MD · Contact
  • Center_12
    Naples, Italy
    Recruiting
    • MD · Contact
  • Center_13
    Naples, Italy
    Recruiting
    • MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 44 months is above that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
Apr 24, 2020
StartActual
Mar 17, 2023
Primary completionEst.
Dec 3, 2026
CompletionEst.
Dec 3, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04358146
Lead sponsor
United Pharmaceuticals
Collaborators
Statitec
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
Mar 17, 2023
Primary completion
Dec 3, 2026 (estimated)
Completion
Dec 3, 2026 (estimated)
Last update
May 4, 2026

Study contacts

Magalie JEGAT
Contact
m.jegat@novalac.com
+330155372222
ANNE-SOPHIE GARREAU
Contact
as.garreau@novalac.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion